Literature DB >> 12768018

Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding.

Shaun R Opie1, Kenneth H Warrington, Mavis Agbandje-McKenna, Sergei Zolotukhin, Nicholas Muzyczka.   

Abstract

The adeno-associated virus type 2 (AAV2) uses heparan sulfate proteoglycan (HSPG) as its primary cellular receptor. In order to identify amino acids within the capsid of AAV2 that contribute to HSPG association, we used biochemical information about heparin and heparin sulfate, AAV serotype protein sequence alignments, and data from previous capsid studies to select residues for mutagenesis. Charged-to-alanine substitution mutagenesis was performed on individual residues and combinations of basic residues for the production and purification of recombinant viruses that contained a green fluorescent protein (GFP) reporter gene cassette. Intact capsids were assayed for their ability to bind to heparin-agarose in vitro, and virions that packaged DNA were assayed for their ability to transduce normally permissive cell lines. We found that mutation of arginine residues at position 585 or 588 eliminated binding to heparin-agarose. Mutation of residues R484, R487, and K532 showed partial binding to heparin-agarose. We observed a general correlation between heparin-agarose binding and infectivity as measured by GFP transduction; however, a subset of mutants that partially bound heparin-agarose (R484A and K532A) were completely noninfectious, suggesting that they had additional blocks to infectivity that were unrelated to heparin binding. Conservative mutation of positions R585 and R588 to lysine slightly reduced heparin-agarose binding and had comparable effects on infectivity. Substitution of AAV2 residues 585 through 590 into a location predicted to be structurally equivalent in AAV5 generated a hybrid virus that bound to heparin-agarose efficiently and was able to package DNA but was noninfectious. Taken together, our results suggest that residues R585 and R588 are primarily responsible for heparin sulfate binding and that mutation of these residues has little effect on other aspects of the viral life cycle. Interactive computer graphics examination of the AAV2 VP3 atomic coordinates revealed that residues which contribute to heparin binding formed a cluster of five basic amino acids that presented toward the icosahedral threefold axis from the surrounding spike protrusion. Three other kinds of mutants were identified. Mutants R459A, H509A, and H526A/K527A bound heparin at levels comparable to that of wild-type virus but were defective for transduction. Another mutant, H358A, was defective for capsid assembly. Finally, an R459A mutant produced significantly lower levels of full capsids, suggesting a packaging defect.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12768018      PMCID: PMC156206          DOI: 10.1128/jvi.77.12.6995-7006.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  56 in total

1.  Sequences required for coordinate induction of adeno-associated virus p19 and p40 promoters by Rep protein.

Authors:  D M McCarty; M Christensen; N Muzyczka
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

2.  Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons.

Authors:  A Nicholls; K A Sharp; B Honig
Journal:  Proteins       Date:  1991

3.  Woodchuck hepatitis virus contains a tripartite posttranscriptional regulatory element.

Authors:  J E Donello; J E Loeb; T J Hope
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

4.  Selective extraction of polyoma DNA from infected mouse cell cultures.

Authors:  B Hirt
Journal:  J Mol Biol       Date:  1967-06-14       Impact factor: 5.469

5.  Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2.

Authors:  A Girod; M Ried; C Wobus; H Lahm; K Leike; J Kleinschmidt; G Deléage; M Hallek
Journal:  Nat Med       Date:  1999-09       Impact factor: 53.440

6.  Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions.

Authors:  C Summerford; R J Samulski
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

7.  Subcellular compartmentalization of adeno-associated virus type 2 assembly.

Authors:  A Wistuba; A Kern; S Weger; D Grimm; J A Kleinschmidt
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

8.  Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2.

Authors:  E A Rutledge; C L Halbert; D W Russell
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

9.  AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection.

Authors:  C Summerford; J S Bartlett; R J Samulski
Journal:  Nat Med       Date:  1999-01       Impact factor: 53.440

10.  Cloning and characterization of adeno-associated virus type 5.

Authors:  J A Chiorini; F Kim; L Yang; R M Kotin
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

View more
  143 in total

1.  Identification of the heparin binding site on adeno-associated virus serotype 3B (AAV-3B).

Authors:  Thomas F Lerch; Michael S Chapman
Journal:  Virology       Date:  2011-12-09       Impact factor: 3.616

Review 2.  Pathways of cell infection by parvoviruses and adeno-associated viruses.

Authors:  Maija Vihinen-Ranta; Sanna Suikkanen; Colin R Parrish
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

3.  Cross-dressing the virion: the transcapsidation of adeno-associated virus serotypes functionally defines subgroups.

Authors:  Joseph E Rabinowitz; Dawn E Bowles; Susan M Faust; Julie G Ledford; Scott E Cunningham; R Jude Samulski
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

4.  Structure of AAV-DJ, a retargeted gene therapy vector: cryo-electron microscopy at 4.5 Å resolution.

Authors:  Thomas F Lerch; Jason K O'Donnell; Nancy L Meyer; Qing Xie; Kenneth A Taylor; Scott M Stagg; Michael S Chapman
Journal:  Structure       Date:  2012-06-21       Impact factor: 5.006

Review 5.  E Pluribus Unum: 50 Years of Research, Millions of Viruses, and One Goal--Tailored Acceleration of AAV Evolution.

Authors:  Dirk Grimm; Sergei Zolotukhin
Journal:  Mol Ther       Date:  2015-09-21       Impact factor: 11.454

Review 6.  Adeno-associated Virus as a Mammalian DNA Vector.

Authors:  Max Salganik; Matthew L Hirsch; Richard Jude Samulski
Journal:  Microbiol Spectr       Date:  2015-08

7.  Vaccines based on novel adeno-associated virus vectors elicit aberrant CD8+ T-cell responses in mice.

Authors:  Jianping Lin; Yan Zhi; Lauren Mays; James M Wilson
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

8.  Role of Tetra Amino Acid Motif Properties on the Function of Protease-Activatable Viral Vectors.

Authors:  T M Robinson; J Judd; M L Ho; J Suh
Journal:  ACS Biomater Sci Eng       Date:  2016-09-28

9.  Identification of a heparin-binding motif on adeno-associated virus type 2 capsids.

Authors:  A Kern; K Schmidt; C Leder; O J Müller; C E Wobus; K Bettinger; C W Von der Lieth; J A King; J A Kleinschmidt
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

10.  CFTR gene transfer with AAV improves early cystic fibrosis pig phenotypes.

Authors:  Benjamin Steines; David D Dickey; Jamie Bergen; Katherine Jda Excoffon; John R Weinstein; Xiaopeng Li; Ziying Yan; Mahmoud H Abou Alaiwa; Viral S Shah; Drake C Bouzek; Linda S Powers; Nicholas D Gansemer; Lynda S Ostedgaard; John F Engelhardt; David A Stoltz; Michael J Welsh; Patrick L Sinn; David V Schaffer; Joseph Zabner
Journal:  JCI Insight       Date:  2016-09-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.